Testosterone undecanoate

Testosterone undecanoate has been studied in 43 papers since 2003: 28 trials and 9 observational studies in people, 3 in animals, 2 reviews; 4 in the past year. It is an approved medicine. The newest paper, Sep 25, 2026: “Testosterone Undecanoate Significantly Reduces Low Density Lipoprotein Cholesterol and Triglycerides in Men With Adult-Onset Testosterone Deficiency”.

InterventionApproved 2014

43 papers study it17 more mention it87 findingsUpdated

PubChemChEBIMeSH

See all 60 papers on testosterone undecanoate

At a glance

Independent labs found the same change in people. 20 independent labs in 15 countries; 160 trials, 17 about aging, 40 with no results posted.

“with a new diagnosis more frequent on TU (3.0% vs 0.4%, P = .03) during, but not after, the study.”
Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up StudyThe Journal of clinical endocrinology and metabolism2023doi:10.1210/clinem/dgad485

2 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 20 independent labs in 15 countries
  • 2 findings against
  • 160 trials, 17 about aging, 40 with no results posted
  • Funders: Bayer and others
  • 15 of 84 findings with company ties
  • 11 of 160 trials sponsored by its developers
  • Human trial28
  • Humans9
  • Animals3
  • In silico1

22 studies gave testosterone undecanoate to people and measured what changed.

What changedDesignPeopleSource

up: Increases appendicular skeletal muscle index64.1% vs 25.3%, p < 0.001

up: Improves grip strength92% vs 67.3%, p = 0.002

down: Decreases frailtyp = 0.01

Randomized trial24 weeks127 peopleMenCirrhosis with sarcopenia receiving nutrition and exerciseHepatology international, Jun 19, 2026

down: Decreases body weightsignificantly greater reduction than group A

up: Increases lean body mass66.1±3.1 kg vs. 63.4±3.0 kg in group A

up: Improves insulin sensitivityHOMA-IR 2.9±0.6 vs. 3.8±0.7

Trial6 months5 peopleMen35-44 yearsPatient cohortsMinerva endocrinology, Mar 9, 2026

up: Improves sexual functionmean increase 2.5 (95% CI, 1.7-3.4) of 30

no change: Has no effect on depressive symptoms

Randomized trial2-year932 peoplemaleaged 50 to 74 yearsMen aged 50 to 74 years with a waist circumference ≥95 cm, impaired glucose tolerance or newly diagnosed type 2 diabetes, and serum testosterone ≤14 nmol/LThe Journal of clinical endocrinology and metabolism, Jun 17, 2025

up: Improves subjective social status

Randomized trial2 years1,007 peoplemaleaged 50 to 74 yearsMen aged 50 to 74 years with a waist circumference ≥95 cm, impaired glucose tolerance or newly diagnosed T2D, and fasting serum testosterone ≤14 nmol/LThe Journal of clinical endocrinology and metabolism, Jul 12, 2024

down: Decreases gynoid and leg fat

Randomized trial20 weeks192 peopleAll participants were males≥70 years of ageMales ≥70 years of age with increased risk of falling but able to walk independentlyJournal of cachexia, sarcopenia and muscle, Jun 18, 2024

What did studies of testosterone undecanoate find?

66

Studies of testosterone undecanoate measured 66 outcomes; the most studied are body weight (6 studies), HbA1c (3) and sexual function (2).

Body weight

downin humans5no changein humans1

6 studies
  1. Testosterone undecanoate decreases body weight in humans (added to tirzepatide in late responders, compared with tirzepatide monotherapy) (significantly greater reduction than group A).

    “At 6 months, group B demonstrated significantly greater body weight and fat mass reduction compared to group A (P<0.05).”

    Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy1000 mg intramuscular6 monthsmalesn = 5

    Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study

    Minerva endocrinology

  2. Testosterone undecanoate showed no clear effect on body weight in humans following VLED and at study end (-11.4 kg vs -10.9 kg, P=0.80).

    “Cases and controls lost the same weight after VLED (testosterone -12.0 kg; placebo -13.5 kg, P=0.40) and maintained this at study end (testosterone -11.4 kg; placebo -10.9 kg, P=0.80).”

    Human trialfollowing VLED and at study endintramuscular56 weeksmalesn = 100

    Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial

    International journal of obesity (2005)

  3. Testosterone undecanoate decreases body weight in men without depression.

    “There was significant reduction in waist circumference, weight, and body mass index in men without depression”

    Human trialin men without depressionmales

    Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study

    The journal of sexual medicine

  4. Testosterone undecanoate decreases body weight in humans (hypogonadal men).

    “Obese men and men with the largest waist circumference showed the strongest declines over 2 years in weight, waist circumference and body mass index (BMI)”

    Human trialhypogonadal menparenteral2 yearsmalesn = 110

    Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome

    Hormone molecular biology and clinical investigation

  5. Testosterone undecanoate decreases body weight in humans.

    “There were significant decreases in weight, BMI and WC in the TU vs placebo group.”

    Human trialparenteral1000 mg IM30 weeksmalesn = 184

    Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study

    Clinical endocrinology

  6. Testosterone undecanoate decreases body weight in humans (type 2 diabetes, visceral obesity and androgen deficiency) (-2.66% body weight, -3.96% waist-hip ratio, -5.65% body fat).

    “TU had a positive effect on (visceral) obesity: statistically significant reduction in body weight (2.66%), waist-hip ratio (-3.96%) and body fat (-5.65%)”

    Human trialtype 2 diabetes, visceral obesity and androgen deficiencyoral120 mg daily3 monthsmalesn = 24

    Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency

    The aging male : the official journal of the International Society for the Study of the Aging Male

HbA1c

downin humans3

3 studies
  1. Testosterone undecanoate decreases HbA1c in obese hypogonadal males with type 2 diabetes mellitus (reduction by 0.94 ± 0.88% points (p < .001)).

    “HbA1c by 0.94 ± 0.88% points (p < .001)”

    Human trialin obese hypogonadal males with type 2 diabetes mellitus1000 mg i.m. every 10 weeksone-yearmalesn = 28

    The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes

    The aging male : the official journal of the International Society for the Study of the Aging Male

  2. Testosterone undecanoate decreases HbA1c in poorly controlled patients with baseline HbA1c > 7.5% (-0.41% within 6 weeks).

    “where the reduction was 0.41% within 6 weeks, and a further 0.46% after 52 weeks of open-label use”

    Human trialin poorly controlled patients with baseline HbA1c > 7.5%6 weeksmales

    Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study

    The journal of sexual medicine

  3. Testosterone undecanoate decreases HbA1c in humans (type 2 diabetes, visceral obesity and androgen deficiency) (from 10.4 to 8.6%).

    “TU significantly improved metabolic control: decrease in blood glucose values and mean glycated hemoglobin (HbA1c) (from 10.4 to 8.6%).”

    Human trialtype 2 diabetes, visceral obesity and androgen deficiencyoral120 mg daily3 monthsmalesn = 24

    Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency

    The aging male : the official journal of the International Society for the Study of the Aging Male

More on HbA1c

Sexual function

upin humans2

2 studies
  1. Testosterone undecanoate improves sexual function in humans (added to tirzepatide in late responders, compared with tirzepatide monotherapy) (IIEF-5 23.2±2.1 vs. 18.0±1.5).

    “sexual health (IIEF-5: 23.2±2.1 vs. 18.0±1.5, P<0.001)”

    Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy1000 mg intramuscular6 monthsmalesn = 5

    Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study

    Minerva endocrinology

  2. Testosterone undecanoate improves sexual function in humans (on the background of a WW lifestyle program) (mean increase 2.5 (95% CI, 1.7-3.4) of 30).

    “There was an effect of testosterone treatment on each of the 5 individual IIEF-15 domains, with the largest effects appearing at 54 weeks.”

    Human trialon the background of a WW lifestyle program2-yearmalesn = 932

    Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial

    The Journal of clinical endocrinology and metabolism

  3. Testosterone undecanoate improves sexual function in humans (at high risk of, or newly diagnosed with, type 2 diabetes).

    “Testosterone treatment improved all 5 International Index of Erectile Function-15 domain scores”

    Human trialat high risk of, or newly diagnosed with, type 2 diabetesintramuscular1000 mg2 yearsmalesn = 792

    Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial

    The Journal of clinical endocrinology and metabolism

Total cholesterol

downin humans2

2 studies
  1. Testosterone undecanoate decreases total cholesterol in humans.

    “Testosterone replacement therapy significantly improved HbA1c, total cholesterol, and waist circumference in men with type 2 diabetes.”

    Human trialmales

    Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study

    The journal of sexual medicine

  2. Testosterone undecanoate is linked with lower total cholesterol in humans (adult-onset testosterone deficiency).

    “TC, TG, and LDL-cholesterol decreased in the TU-treated men”

    Humansadult-onset testosterone deficiencymales

    Testosterone Undecanoate Significantly Reduces Low Density Lipoprotein Cholesterol and Triglycerides in Men With Adult-Onset Testosterone Deficiency

    Andrology

More on Total cholesterol

Insulin sensitivity

upin humans2

2 studies
  1. Testosterone undecanoate improves insulin sensitivity in humans (added to tirzepatide in late responders, compared with tirzepatide monotherapy) (HOMA-IR 2.9±0.6 vs. 3.8±0.7).

    “superior improvements in insulin sensitivity (HOMA-IR: 2.9±0.6 vs. 3.8±0.7, P<0.01)”

    Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy1000 mg intramuscular6 monthsmalesn = 5

    Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study

    Minerva endocrinology

  2. Testosterone undecanoate improves insulin sensitivity in humans (obese men with severe OSA on a hypocaloric diet) (-1.14 units, 95% CI -2.27 to -0.01, P<0.05).

    “testosterone treatment increased insulin sensitivity (-1.14 units, 95% confidence interval (95% CI) -2.27 to -0.01, P<0.05)”

    Human trialobese men with severe OSA on a hypocaloric diettestosterone undecanoate i.m. injections1000 mg18 weeksmalesn = 67

    Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial

    European journal of endocrinology

Lean body mass

upin humans2

2 studies
  1. Testosterone undecanoate increases lean body mass in humans (66.1±3.1 kg vs. 63.4±3.0 kg in group A).

    “group B achieved significant LBM recovery (66.1±3.1 kg vs. 63.4±3.0 kg in group A, P<0.01).”

    Human trialadded to tirzepatide in late responders, compared with tirzepatide monotherapy, where group A lost lean mass1000 mg intramuscular6 monthsmalesn = 5

    Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study

    Minerva endocrinology

  2. Testosterone undecanoate increases lean body mass in humans (oophorectomized women on estradiol valerate 2 mg daily).

    “A significant increase was seen in total lean body mass with the estrogen/testosterone regimen”

    Human trialoophorectomized women on estradiol valerate 2 mg daily40 mg daily24 weeksfemalesn = 44

    Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

C-reactive protein

downin humans1no changein humans1

2 studies
  1. Testosterone undecanoate decreases C-reactive protein in humans.

    “Of the inflammatory markers, IL-1β, TNF-α and CRP decreased, while IL-6 and IL-10 did not change significantly.”

    Human trialparenteral1000 mg IM30 weeksmalesn = 184

    Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study

    Clinical endocrinology

  2. Testosterone undecanoate showed no clear effect on C-reactive protein in humans (low testosterone levels (<13.7 nmol/L)) (median hs-CRP 2.20 vs 2.00 mg/L, P = .36).

    “After 26 weeks of testosterone supplementation therapy, the 2 intervention groups were not statistically significantly different (median hs-CRP 2.20 vs 2.00 mg/L, interquartile range 0.40-6.54 vs 0.50-5.70, P = .36).”

    Human triallow testosterone levels (<13.7 nmol/L)capsulesserum160 mg daily26 weeksmalesn = 237

    Oral testosterone supplementation and chronic low-grade inflammation in elderly men: a 26-week randomized, placebo-controlled trial

    American heart journal

More on C-reactive protein

Sperm concentration

downin humans1

1 study
  1. Testosterone undecanoate decreases sperm concentration in humans.

    “sperm concentration and total number decreased significantly in the TRT group”

    Human trial1000 mg per 10-12 weeks24 weeksmalesn = 25

    Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism

    Diabetes, obesity & metabolism

  2. Testosterone undecanoate decreases sperm concentration in humans (relative change −0.67 (−88; −54)).

    “In the TRT group, there was a significant decrease in sperm concentration (relative change −0.67 (−88; −54), p = 0.028) and total number (relative change −0.59 (−87; 50), p = 0.018).”

    Human trial24 weeks

    Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism

    Diabetes, obesity & metabolism

More on Sperm concentration

Triglyceride

downin humans1

1 study
  1. Testosterone undecanoate is linked with lower triglyceride in humans (adult-onset testosterone deficiency).

    “significant decrease in LDL-cholesterol and TG (mostly in the initial 24 months) in the TU-treated men”

    Humansadult-onset testosterone deficiencymales

    Testosterone Undecanoate Significantly Reduces Low Density Lipoprotein Cholesterol and Triglycerides in Men With Adult-Onset Testosterone Deficiency

    Andrology

More on Triglyceride

Low-density lipoprotein cholesterol

downin humans1

1 study
  1. Testosterone undecanoate is linked with lower low-density lipoprotein cholesterol in humans (adult-onset testosterone deficiency).

    “significant decrease in LDL-cholesterol and TG (mostly in the initial 24 months) in the TU-treated men”

    Humansadult-onset testosterone deficiencymales

    Testosterone Undecanoate Significantly Reduces Low Density Lipoprotein Cholesterol and Triglycerides in Men With Adult-Onset Testosterone Deficiency

    Andrology

More on Low-density lipoprotein cholesterol

Ammonia

downin humans1

1 study
  1. Testosterone undecanoate decreases ammonia in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (64% vs 25%, p = 0.01).

    “reduction in serum ammonia (64% vs. 25%, p = 0.01).”

    Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 102

    Testosterone adds to muscle gains in men with cirrhosis

    Hepatology international

More on Ammonia

Hospitalization

downin humans1

1 study
  1. Testosterone undecanoate decreases hospitalization in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (18% vs 34.6%, p = 0.05).

    “Hospitalization rates were lower in the NExT group (18% vs. 34.6%, p = 0.05)”

    Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 102

    Testosterone adds to muscle gains in men with cirrhosis

    Hepatology international

Frailty

downin humans1

1 study
  1. Testosterone undecanoate decreases frailty in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (p = 0.01).

    “Liver frailty index improved significantly in the NExT group compared with the NEx group at 24 weeks (3.98 ± 0.27 to 3.32 ± 0.21 vs. 3.93 ± 0.24 to 3.68 ± 0.22, respectively; p = 0.01).”

    Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 102

    Testosterone adds to muscle gains in men with cirrhosis

    Hepatology international

Grip strength

upin humans1

1 study
  1. Testosterone undecanoate improves grip strength in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (92% vs 67.3%, p = 0.002).

    “A greater proportion of patients in the NExT group demonstrated improvement in hand-grip strength (92% vs. 67.3%, p = 0.002)”

    Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 102

    Testosterone adds to muscle gains in men with cirrhosis

    Hepatology international

Appendicular skeletal muscle index

upin humans1

1 study
  1. Testosterone undecanoate increases appendicular skeletal muscle index in humans (cirrhosis with sarcopenia receiving nutrition and exercise) (64.1% vs 25.3%, p < 0.001).

    “a ≥ 10% increase in ASMI was achieved in 41/64 (64.1%) patients in the NExT group compared with 16/63 (25.3%) in the NEx group (p < 0.001).”

    Human trialcirrhosis with sarcopenia receiving nutrition and exerciseintramuscular injection1000 mg24 weeksmalesn = 127

    Testosterone adds to muscle gains in men with cirrhosis

    Hepatology international

All 66

What is testosterone undecanoate linked with?

5

Studies link testosterone undecanoate with 5 measures, among them mortality, type 2 diabetes and blood pressure.

Mortality

downin humans2HR 0.23

2 studies
  1. Testosterone undecanoate is associated with mortality in humans (adult-onset testosterone deficiency; compared with men opting against treatment).

    “Mortality was lower (p < 0.001) in men on TU compared to men opting against TU.”

    Humansadult-onset testosterone deficiency; compared with men opting against treatmentnearly 9 yearsmalesn = 737

    The association between age and mortality in men with adult-onset testosterone deficiency is altered by testosterone therapy

    The aging male : the official journal of the International Society for the Study of the Aging Male

  2. Testosterone undecanoate is linked with a lower risk of mortality in humans (adult-onset testosterone deficiency) (HR 0.23, 95% CI 0.14-0.40).

    “TU (ref: non-treatment) was associated with mortality; hazard ratio = 0.23, 95% confidence intervals = 0.14-0.40.”

    Humansadult-onset testosterone deficiencynear 10-year follow-upmalesn = 737

    Testosterone replacement therapy: association with mortality in high-risk patient subgroups

    Andrology

Type 2 diabetes

downin humans2−40%OR 0.48

2 studies
  1. Testosterone undecanoate lowers the risk of type 2 diabetes in humans (impaired glucose tolerance or newly diagnosed type 2 diabetes) (adjusted OR 0.48 (95% CI: .30-.76)).

    “which became 0.48 (95% CI:.30-.76) after adjustment for covariates.”

    Human trialimpaired glucose tolerance or newly diagnosed type 2 diabetesinjections1000 mg every 3 months2 yearsmalesn = 709

    Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trial

    European journal of endocrinology

  2. Testosterone undecanoate lowers the risk of type 2 diabetes in humans (-40%).

    “with testosterone (T) treatment reducing diabetes diagnosis by 40%.”

    Reviewinjections24 monthsmalesn = 1,007

    Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study

    The Journal of clinical endocrinology and metabolism

More on Type 2 diabetes

Blood pressure

downin humans1

1 study
  1. Testosterone undecanoate is associated with blood pressure in humans (adult-onset testosterone deficiency) (Without antihypertensive agents: median systolic BP change −12.5 mmHg, diastolic BP change −8.0 mmHg, and pulse pressure change −6.0 mmHg).

    “TU was associated with significant reductions in systolic, diastolic BP and pulse pressure, regardless of antihypertensive therapy”

    Humansadult-onset testosterone deficiencymales

    Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men

    The world journal of men's health

Sleep apnea

upin humans1

1 study
  1. Testosterone undecanoate raises the risk of sleep apnea in humans (3.0% vs 0.4%, P = .03).

    “with a new diagnosis more frequent on TU (3.0% vs 0.4%, P = .03) during, but not after, the study.”

    Human trialduring the studymalesn = 1,007

    Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study

    The Journal of clinical endocrinology and metabolism

More on Sleep apnea

Serum metabolites

mixedin humans1

1 study
  1. Testosterone undecanoate is associated with serum metabolites in humans.

    “cystine, lysine and tyrosine were shown to change in correlation with insulin sensitivity and high-density lipoprotein cholesterol levels in response to testosterone”

    Human trialserum40 mg every second day3 monthsfemales

    Effects of oestrogen and testosterone therapy on serum metabolites in postmenopausal women

    Clinical endocrinology

More on Serum metabolites

Has testosterone undecanoate been tested in people?

17 of 160 about aging

Yes: 28 trials and 9 observational studies in people have been published, and 154 trials are registered.

Latest change Spinal cord injury: Phase 2 → Phase 2/3Oct 31, 2026

Approved

  • FDA Aveed

    Mar 5, 2014primary hypogonadism, hypogonadotropic hypogonadism, testicular failure

  • FDA Jatenzo

    Mar 27, 2019primary hypogonadism, hypogonadotropic hypogonadism, testicular failure

  • FDA Tlando

    Mar 28, 2022primary hypogonadism, hypogonadotropic hypogonadism, testicular failure

  • FDA Kyzatrex

    Jul 27, 2022primary hypogonadism, hypogonadotropic hypogonadism, testicular failure

Repurposing

40 of 75

Every condition in trials

  • Eunuchism

    Phase 4Results posted20 trials

  • Prostatic neoplasm

    Phase 4Recruiting16 trials

  • Gonadal Disorders

    Phase 4Status unknown6 trials

  • Motor Activity

    Phase 4Results posted5 trials

  • Psychological sexual dysfunction

    Phase 3Completed5 trials

  • Physiological sexual dysfunction

    Phase 3Status unknown2 trials

All 11

Stopped

  • NCT00240981TerminatedHypogonadism

    Higher incidence of cardiovascular events in the testosterone arm of the trial. Decision taken by the DSMB on December 31st, 2009.

  • NCT01084369TerminatedHypogonadism

    Withdrawal of sponsorship

  • NCT04807894TerminatedUrinary tract infection

    High rates of loss to follow up

  • NCT02418572TerminatedInfertility

    Having reached the sample size described for the interim analysis and having seen the post-interim results, the sponsor has decided to stop the trial due to futility.

  • NCT02248701TerminatedSpinal cord injury

    Enrollment difficulties

  • NCT01516554TerminatedMultiple sclerosis

    Poor recruitment

All 7

Who is developing testosterone undecanoate?

1 company: Lipocine.

Companies
  • LipocinePhase 2NASH - nonalcoholic steatohepatitis

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 1Aug 2026: 1Sep 2026: 1Oct 2026: 0Nov 2026: 05 papers in 12 months
Hepatology International

Testosterone adds to muscle gains in men with cirrhosis

At 24 weeks, an arm-and-leg muscle mass index rose at least 10% in 64.1% given added testosterone, versus 25.3% with nutrition and exercise alone.At 24 weeks, an arm-and-leg muscle mass index rose at least 10% in 64.1% given added testosterone, versus 25.3% with nutrition and exercise alone.

Randomized trial · 127 peopleCirrhosis

See all 60 papers on testosterone undecanoate